Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.
Metastatic kidney cancer patients who took a proprietary live bacterial supplement showed signs of gut health that could improve their outcomes, in an early trial of cabozantinib and nivolumab.
In this study, patients with intermediate/high risk kidney cancer were given the immunotherapy, nivolumab before surgery followed by nivolumab after surgery (adjuvant nivolumab) to see if this treatment improved recurrence-free survival compared to surgery alone.
"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
A comprehensive single-cell analysis of clear cell renal cell carcinoma reveals a previously uncharacterized tip-cell like endothelial phenotype and uncovers immunosuppressive clinically relevant targetable interactions in the tumor microenvironment.
HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.
"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
In a randomized phase 1 trial, the addition of a live Clostridium species-containing product to a tyrosine kinase inhibitor and anti-programmed cell death protein 1 treatment combination did not increase bacterial abundance of Bifidobacterium spp. but enhanced clinical responses in ...
Dr Katy Beckermann introduces the panel of experts and addresses the first clinical case in this series, highlighting intermediate-risk, metastatic clear cell renal cell carcinoma.
During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.